Edoxaban versus warfarin in patients with atrial fibrillation

Robert P Giugliano; Christian T Ruff; Eugene Braunwald; Sabina A Murphy; Stephen D Wiviott; Jonathan L Halperin; Albert L Waldo; Michael D Ezekowitz; Jeffrey I Weitz; Jindřich Špinar; Witold Ruzyllo; Mikhail Ruda; Yukihiro Koretsune; Joshua Betcher; Minggao Shi; Laura T Grip; Shirali P Patel; Indravadan Patel; James J Hanyok; Michele Mercuri; Elliott M Antman; ENGAGE AF-TIMI 48 Investigators; Christian Hassager

doi:10.1056/NEJMoa1310907

Edoxaban versus warfarin in patients with atrial fibrillation

Robert P Giugliano, Christian T Ruff, Eugene Braunwald, Sabina A Murphy, Stephen D Wiviott, Jonathan L Halperin, Albert L Waldo, Michael D Ezekowitz, Jeffrey I Weitz, Jindřich Špinar, Witold Ruzyllo, Mikhail Ruda, Yukihiro Koretsune, Joshua Betcher, Minggao Shi, Laura T Grip, Shirali P Patel, Indravadan Patel, James J Hanyok, Michele MercuriElliott M Antman, ENGAGE AF-TIMI 48 Investigators, Christian Hassager (Medlem af forfattergruppering)

4294 Citationer (Scopus)

Abstract

Edoxaban is a direct oral factor Xa inhibitor with proven antithrombotic effects. The long-term efficacy and safety of edoxaban as compared with warfarin in patients with atrial fibrillation is not known.

Originalsprog	Engelsk
Tidsskrift	The New England journal of medicine
Vol/bind	369
Udgave nummer	22
Sider (fra-til)	2093-104
Antal sider	12
ISSN	0028-4793
DOI	https://doi.org/10.1056/NEJMoa1310907
Status	Udgivet - 28 nov. 2013

Adgang til dokumentet

10.1056/NEJMoa1310907

Citationsformater

Giugliano, R. P., Ruff, C. T., Braunwald, E., Murphy, S. A., Wiviott, S. D., Halperin, J. L., Waldo, A. L., Ezekowitz, M. D., Weitz, J. I., Špinar, J., Ruzyllo, W., Ruda, M., Koretsune, Y., Betcher, J., Shi, M., Grip, L. T., Patel, S. P., Patel, I., Hanyok, J. J., ... Hassager, C. (2013). Edoxaban versus warfarin in patients with atrial fibrillation. The New England journal of medicine, 369(22), 2093-104. https://doi.org/10.1056/NEJMoa1310907

Giugliano, RP, Ruff, CT, Braunwald, E, Murphy, SA, Wiviott, SD, Halperin, JL, Waldo, AL, Ezekowitz, MD, Weitz, JI, Špinar, J, Ruzyllo, W, Ruda, M, Koretsune, Y, Betcher, J, Shi, M, Grip, LT, Patel, SP, Patel, I, Hanyok, JJ, Mercuri, M, Antman, EM, ENGAGE AF-TIMI 48 Investigators & Hassager, C 2013, 'Edoxaban versus warfarin in patients with atrial fibrillation', The New England journal of medicine, bind 369, nr. 22, s. 2093-104. https://doi.org/10.1056/NEJMoa1310907

@article{e820fe21bca7404d9fbd6ae71f32d1e8,

title = "Edoxaban versus warfarin in patients with atrial fibrillation",

abstract = "Edoxaban is a direct oral factor Xa inhibitor with proven antithrombotic effects. The long-term efficacy and safety of edoxaban as compared with warfarin in patients with atrial fibrillation is not known.",

keywords = "Adult, Aged, Anticoagulants, Atrial Fibrillation, Cardiovascular Diseases, Double-Blind Method, Embolism, Enoxaparin, Female, Follow-Up Studies, Hemorrhage, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Stroke, Warfarin",

author = "Giugliano, {Robert P} and Ruff, {Christian T} and Eugene Braunwald and Murphy, {Sabina A} and Wiviott, {Stephen D} and Halperin, {Jonathan L} and Waldo, {Albert L} and Ezekowitz, {Michael D} and Weitz, {Jeffrey I} and Jind{\v r}ich {\v S}pinar and Witold Ruzyllo and Mikhail Ruda and Yukihiro Koretsune and Joshua Betcher and Minggao Shi and Grip, {Laura T} and Patel, {Shirali P} and Indravadan Patel and Hanyok, {James J} and Michele Mercuri and Antman, {Elliott M} and {ENGAGE AF-TIMI 48 Investigators} and Christian Hassager",

note = "From Brigham and Women's Hospital and Harvard Medical School, Boston (R.P.G., C.T.R., E.B., S.A.M., S.D.W., L.T.G., E.M.A.); Mount Sinai Medical Center, New York (J.L.H.); University Hospitals Case Medical Center, Cleveland (A.L.W.); Thomas Jefferson Medical College, Philadelphia (M.D.E.); McMaster University, Hamilton, ON, Canada (J.I.W.); University Hospital, Jihlavska, Brno, Czech Republic (J.S.); Institute of Cardiology, Warsaw, Poland (W.R.); Cardiology Research Center, Moscow (M.R.); National Hospital Organization, Osaka National Hospital, Osaka, Japan (Y.K.); Quintiles, Durham, NC (J.B., S.P.P.); and Daiichi Sankyo Pharma Development, Edison, NJ (M.S., I.P., J.J.H., M.M.).",

year = "2013",

month = nov,

day = "28",

doi = "10.1056/NEJMoa1310907",

language = "English",

volume = "369",

pages = "2093--104",

journal = "The New England journal of medicine",

issn = "0028-4793",

publisher = "Massachusetts Medical Society",

number = "22",

}

TY - JOUR

T1 - Edoxaban versus warfarin in patients with atrial fibrillation

AU - Giugliano, Robert P

AU - Ruff, Christian T

AU - Braunwald, Eugene

AU - Murphy, Sabina A

AU - Wiviott, Stephen D

AU - Halperin, Jonathan L

AU - Waldo, Albert L

AU - Ezekowitz, Michael D

AU - Weitz, Jeffrey I

AU - Špinar, Jindřich

AU - Ruzyllo, Witold

AU - Ruda, Mikhail

AU - Koretsune, Yukihiro

AU - Betcher, Joshua

AU - Shi, Minggao

AU - Grip, Laura T

AU - Patel, Shirali P

AU - Patel, Indravadan

AU - Hanyok, James J

AU - Mercuri, Michele

AU - Antman, Elliott M

AU - ENGAGE AF-TIMI 48 Investigators

A2 - Hassager, Christian

N1 - From Brigham and Women's Hospital and Harvard Medical School, Boston (R.P.G., C.T.R., E.B., S.A.M., S.D.W., L.T.G., E.M.A.); Mount Sinai Medical Center, New York (J.L.H.); University Hospitals Case Medical Center, Cleveland (A.L.W.); Thomas Jefferson Medical College, Philadelphia (M.D.E.); McMaster University, Hamilton, ON, Canada (J.I.W.); University Hospital, Jihlavska, Brno, Czech Republic (J.S.); Institute of Cardiology, Warsaw, Poland (W.R.); Cardiology Research Center, Moscow (M.R.); National Hospital Organization, Osaka National Hospital, Osaka, Japan (Y.K.); Quintiles, Durham, NC (J.B., S.P.P.); and Daiichi Sankyo Pharma Development, Edison, NJ (M.S., I.P., J.J.H., M.M.).

PY - 2013/11/28

Y1 - 2013/11/28

N2 - Edoxaban is a direct oral factor Xa inhibitor with proven antithrombotic effects. The long-term efficacy and safety of edoxaban as compared with warfarin in patients with atrial fibrillation is not known.

AB - Edoxaban is a direct oral factor Xa inhibitor with proven antithrombotic effects. The long-term efficacy and safety of edoxaban as compared with warfarin in patients with atrial fibrillation is not known.

KW - Adult

KW - Aged

KW - Anticoagulants

KW - Atrial Fibrillation

KW - Cardiovascular Diseases

KW - Double-Blind Method

KW - Embolism

KW - Enoxaparin

KW - Female

KW - Follow-Up Studies

KW - Hemorrhage

KW - Humans

KW - Kaplan-Meier Estimate

KW - Male

KW - Middle Aged

KW - Stroke

KW - Warfarin

U2 - 10.1056/NEJMoa1310907

DO - 10.1056/NEJMoa1310907

M3 - Journal article

C2 - 24251359

SN - 0028-4793

VL - 369

SP - 2093

EP - 2104

JO - The New England journal of medicine

JF - The New England journal of medicine

IS - 22

ER -

Edoxaban versus warfarin in patients with atrial fibrillation

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater